Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orthokine plus ozone therapy versus Orthokine plus placebo for knee osteoarthritis
IRCT20230311057677N1Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of autologous conditioned serum, medical ozonated water and lidocaine in knee osteoarthritis (OA) (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoint: Pain intensity at 6 months. Started Aug 2023; status: completed.
02
Drugs
autologous conditioned serummedical ozonated waterlidocaine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20230311057677N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230311057677N1.